News article | 8th Oct 2026ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
News article | 2nd Oct 2026Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
News article | 1st Oct 2026Long-Acting HIV Treatment and PrEP: How Weekly Oral and Injectable Therapies Could Change Adherence and Patient Choice
News article | 22nd Sep 2026The Most Expensive CI Failure is Missing the Moment Your Strategic Assumption Became Wrong
News article | 31st Aug 2026Pharma Has More Data Than Ever, This Doesn’t Mean It Has Better Intelligence
News article | 27th Aug 2026Beyond Amyloid, Part Two (of two): Delivery, Diagnostics and the Path to Combination Care
News article | 26th Aug 2026Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
News article | 18th Aug 2026Immune Reset In Rheumatology: Moving Beyond Disease Suppression Toward Durable Remission
News article | 21st Jul 2026From valency to vaccine design: The changing competitive landscape in Pneumococcal vaccines
News article | 23rd Jun 2026The next chapter of obesity and Type 2 Diabetes care: ADA 2026 signals a more personalized future
News article | 4th Jun 2026The changing multiple sclerosis landscape: Earlier diagnosis, improved monitoring, and a more competitive race for durable disease control
News article | 4th Jun 2026Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
